Can-Fite BioPharma (CANF) Operating Income Growth (3y) (2017 - 2023)
Can-Fite BioPharma (CANF) Operating Income Growth (3y) (2017 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.70% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 8.36% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 69.02% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 24.14% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 44.54% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 44.34% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -28.30% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 81.27% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -18.82% |
| 10 | Can-Fite BioPharma | 2.76 Mn | -8.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 19.78% |
| Sep 30, 2023 | 9.05% |
| Jun 30, 2023 | 22.49% |
| Mar 31, 2023 | 14.08% |
| Dec 31, 2022 | 36.48% |
| Sep 30, 2022 | 2.67% |
| Jun 30, 2022 | 31.05% |
| Mar 31, 2022 | -50.15% |
| Dec 31, 2021 | -17.19% |
| Sep 30, 2021 | -95.31% |
| Jun 30, 2021 | 15.23% |
| Mar 31, 2021 | -49.88% |
| Dec 31, 2020 | 33.53% |
| Sep 30, 2020 | -58.73% |
| Jun 30, 2020 | -39.00% |
| Mar 31, 2020 | -30.73% |
| Dec 31, 2019 | 32.08% |
| Sep 30, 2019 | -47.93% |
| Jun 30, 2019 | -70.66% |
| Mar 31, 2019 | 1.14% |